A share price of Marinus Pharmaceuticals Inc [MRNS] is currently trading at $0.55, down -0.25%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The MRNS shares have gain 1.48% over the last week, with a monthly amount glided 2.81%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Marinus Pharmaceuticals Inc [NASDAQ: MRNS] stock has seen the most recent analyst activity on September 23, 2024, when Oppenheimer upgraded its rating to a Outperform but kept the price target unchanged to $6 for it. Previously, Ladenburg Thalmann downgraded its rating to Neutral on August 14, 2024. On April 16, 2024, downgrade downgraded it’s rating to Neutral and revised its price target to $2 on the stock. RBC Capital Mkts downgraded its rating to a Sector Perform and decreased its price target to $3 on April 15, 2024. Oppenheimer downgraded its rating to a Perform and reduced its price target to $9 on August 11, 2023. RBC Capital Mkts started tracking with a Outperform rating for this stock on January 20, 2023, and assigned it a price target of $23. In a note dated September 30, 2020, Truist initiated an Buy rating and provided a target price of $35 on this stock.
Marinus Pharmaceuticals Inc experienced fluctuations in its stock price throughout the past year between $0.22 and $10.50. Currently, Wall Street analysts expect the stock to reach $6 within the next 12 months. Marinus Pharmaceuticals Inc [NASDAQ: MRNS] shares were valued at $0.55 at the most recent close of the market. An investor can expect a potential return of 990.91% based on the average MRNS price forecast.
Analyzing the MRNS fundamentals
Trailing Twelve Months sales for Marinus Pharmaceuticals Inc [NASDAQ:MRNS] were 31.47M which represents 16.39% growth. Gross Profit Margin for this corporation currently stands at 0.89% with Operating Profit Margin at -3.96%, Pretax Profit Margin comes in at -4.46%, and Net Profit Margin reading is -4.46%. To continue investigating profitability, this company’s Return on Assets is posted at -2.21, Equity is 4.94 and Total Capital is -4.28. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -0.84.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.5465 points at the first support level, and at 0.5443 for the second support level. However, for the 1st resistance point, the stock is sitting at 0.5504, and for the 2nd resistance point, it is at 0.5521.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Marinus Pharmaceuticals Inc [NASDAQ:MRNS] is 1.66. Further, the Quick Ratio stands at 1.47, while the Cash Ratio is 1.22. Considering the valuation of this stock, the price to sales ratio is 0.96.
Transactions by insiders
Recent insider trading involved Ezickson Elan, Director, that happened on Jan 21 ’25 when 1600.0 shares were sold. Director, Johnson Marvin completed a deal on Jan 21 ’25 to sell 1610.0 shares. Meanwhile, Director Saraswathy Nochur bought 13250.0 shares on Dec 10 ’24.
